Zydus Lifesciences Limited has informed the Exchange regarding a press release dated Jun 10, 2025, titled "Zydus receives EIR for the API manufacturing facility at Dabhasa".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has received the Establishment Inspection Report (EIR) from the USFDA for its API (Active Pharmaceutical Ingredient) manufacturing facility at Dabhasa, near Vadodara. The USFDA had inspected the facility from April 21 to April 25, 2025, and has now classified the outcome as Voluntary Action Indicated (VAI) and closed the inspection. A VAI classification means the facility was found to have no serious regulatory violations, and no further enforcement action is required. The company disclosed this under SEBI's Regulation 30 listing requirements.
This is a positive regulatory update for shareholders — the VAI classification and closure of inspection means the Dabhasa API facility can continue operating and supplying to the US market without regulatory obstacles, removing any near-term compliance overhang on the stock.